Physician profile
Terri Mcdowell
NPI 1306217450
$4,937.43
in general payments reported to CMS, 2019-2025
29 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $524 · 2022: $534 · 2023: $1,444 · 2024: $1,421 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $7.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,871.71 |
| Education | $7.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $547.11 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $456.61 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.86 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $345.84 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $337.37 | 2021-2025 | |
| Boston Scientific Corporation | $331.02 | 2025 | Watchman Flx, Latitude Communicator Power Supply |
| Amgen INC. | $311.02 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $241.18 | 2021-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $238.62 | 2021-2024 | Nexletol |
| Irhythm Technologies, INC. | $219.79 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.60 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $195.70 | 2021-2025 | Farxiga |
| Celgene Corporation | $179.31 | 2023-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $169.29 | 2021-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $157.27 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90.39 | 2024-2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $81.13 | 2023-2024 | Optimizer, Optimizer |
| Abbott Laboratories | $68.45 | 2021 | |
| Alnylam Pharmaceuticals INC. | $66.59 | 2025 | Amvuttra |
| Amarin Pharma, INC. | $51.94 | 2021 | |
| Edwards Lifesciences Corporation | $42.64 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals, Ltd. | $39.90 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $39.40 | 2024 | Assure Wcd |
| Heartflow, INC. | $35.79 | 2023-2024 | Ffrct |
| Abiomed | $22.71 | 2024 | Impella |
| Smith+Nephew, INC. | $21.85 | 2024 | Renasys Touch, Pico |
| Genzyme Corporation | $20.18 | 2023 | |
| Angiodynamics, INC. | $17.18 | 2023 | Angiovac |
| Lexicon Pharmaceuticals, INC. | $15.69 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.